The Newborn Vitamin K Shot

The vitamin K shot is offered to your baby within minutes of birth. Like many decisions in the birth space, it tends to arrive before you've had a proper chance to sit with it, and for a lot of parents, the noise online makes genuine clarity harder, not easier. What you actually need is the same thing you need for every significant decision in this season: a clear understanding of the benefits, an honest look at the risks, and enough context to hold both with confidence. That is what this article is here to provide.

Quick summary:

• All newborns are born with low vitamin K. This is normal human biology, not a deficiency caused by anything the mother did.
• Without prophylaxis (preventative action or treatment), a small number of infants develop vitamin K deficiency bleeding (VKDB), which can cause brain bleeds and, in severe cases, death.
• Infants who don't receive the Vitamin K injection are approximately 81 times more likely to develop VKDB between one week and six months of life.
• A single intramuscular injection at birth reduces this risk by more than 99 percent.
• The injection contains vitamin K1, glycocholic acid, and lecithin and no heavy metals.
• Proposed links to leukaemia and toxic chemicals have been extensively investigated and not confirmed.
• Vitamin K prophylaxis is recommended by all Australian states and territories and health authorities worldwide.

Why Are Newborns Low in Vitamin K at Birth?

Vitamin K is a fat-soluble vitamin the body uses to produce several proteins involved in blood clotting. Without adequate levels, the blood cannot clot effectively. In a newborn, that matters.

All babies are born with lower vitamin K levels than adults. This is not a fluke; it reflects several biological realities that converge at birth:

• Poor placental transfer: Vitamin K crosses the placenta at roughly a 30:1 ratio. For every 30 units in the mother's blood, only 1 reaches the baby. Even a mother with excellent vitamin K status cannot fully compensate for this.
• Breast milk is low in vitamin K: Breast milk contains approximately 1 to 2 micrograms per litre of vitamin K1. Formula contains roughly 30 micrograms per litre, meaning exclusively breastfed babies are particularly reliant on their own stores, which are already limited at birth.
• No gut bacteria yet: Older infants and adults get a portion of their vitamin K from gut bacteria (as vitamin K2). A newborn's gut is essentially sterile at birth. This protective source takes months to develop.

The result is a genuine physiological gap. Newborns are not deficient because of something a parent has done or not done. It is simply how human biology works at this stage of life.

What Is Vitamin K Deficiency Bleeding (VKDB)?

Vitamin K deficiency bleeding (VKDB) is the term used to describe bleeding in a newborn or young infant caused by insufficient vitamin K to support normal clotting. It was historically called "haemorrhagic disease of the newborn," and it is the condition that vitamin K prophylaxis is designed to prevent.

VKDB is classified into three types based on timing:

Type	Timing	Incidence without prophylaxis	Common presentation
Early VKDB	Within 24 hours of birth	250–1,700 per 100,000 births	Often linked to maternal medication (anticonvulsants, some antibiotics); can be severe
Classic VKDB	Days 2–7	10–35 per 100,000 births	Bruising, umbilical stump bleeding, gastrointestinal bleeding
Late VKDB	Weeks 2–12	10–80 per 100,000 births	Intracranial haemorrhage (brain bleed); often the most serious form

Late VKDB carries the highest stakes. Research shows that 30 to 50 percent of cases involve intracranial haemorrhage, and of those infants who survive, 40 to 55 percent experience permanent neurological damage (Ardell et al., 2010; Mihatsch et al., 2021). It occurs almost exclusively in breastfed infants. This is not because breastfeeding is harmful, but because the natural low vitamin K content of breast milk is not sufficient on its own when a baby's stores are already low at birth.

Key points from this section:

• All newborns are born low in vitamin K. This is biological, not preventable through a mother's diet.
• Breast milk is naturally low in vitamin K1. Exclusively breastfed babies are the most vulnerable group.
• The most serious form, late VKDB, typically causes brain bleeds with no warning signs beforehand.
• Of infants who survive late VKDB intracranial haemorrhage, around half experience permanent neurological damage.

How Did Routine Vitamin K Prophylaxis Come About?

The story of vitamin K prophylaxis is a century in the making. Neonatal bleeding was first formally described by Townsend in 1894, who observed an unexplained bleeding condition in otherwise healthy newborns. For decades, clinicians observed the pattern without a clear cause.

The breakthrough came in 1943, when Henrik Dam and Edward Doisy were awarded the Nobel Prize in Physiology or Medicine for their discovery and synthesis of vitamin K. Their work established the link between the vitamin and clotting function, and opened the door to understanding why newborns were vulnerable.

By the late 1950s, researchers including Brinkhous had demonstrated that bleeding newborns had measurably low clotting factor activity (hypoprothrombinemia), and that this could be corrected with vitamin K administration. In 1961, the American Academy of Pediatrics issued its first formal recommendation that all newborns receive parenteral vitamin K prophylaxis, a recommendation that has been upheld, reviewed, and reaffirmed many times since (Takahashi et al., 2020).

Early formulations used water-soluble vitamin K analogues, but these were withdrawn in 1961 after reports of adverse effects in premature infants at very high doses. The current standard formulation, phytomenadione (vitamin K1) in the mixed micelle (MM) form used in Australia, has a well-established safety record accumulated over decades.

What Did the Introduction of Routine Vitamin K Achieve?

The population-level effect of routine vitamin K prophylaxis has been substantial and measurable. Before unpacking the numbers, it helps to understand how they are categorised, because the figures that circulate in this space refer to different subsets of the same condition, and mixing them creates unnecessary confusion.

VKDB is reported in three categories, each with its own incidence rate in unprotected infants:

• All forms combined (early, classic, and late): estimated at approximately 1,700 per 100,000 unprotected births across historical data.
• Classic VKDB (days 2 to 7): occurs in roughly 10 to 35 per 100,000 unprotected births.
• Late VKDB (weeks 2 to 12): occurs in 10 to 80 per 100,000 unprotected breastfed infants. This is the form most likely to cause brain bleeds.

With a single intramuscular injection at birth, all-form VKDB incidence has fallen to fewer than 1 per 100,000 in countries with universal programs. That is a reduction of more than 99 percent. For late VKDB specifically, IM prophylaxis brings the rate down to fewer than 0.3 per 100,000, compared to up to 80 per 100,000 without it, a reduction of more than 99 percent in the most dangerous form (Mihatsch et al., 2021).

Australian data reinforces this picture. A 24-year surveillance study conducted through the Australian Paediatric Surveillance Unit (APSU) tracked VKDB in Australian infants from 1993 to 2017. Over this period, 58 confirmed cases of VKDB were identified in Australia. Of these, 6 infants died from intracranial haemorrhage. Critically, 3 of those deaths were directly linked to home delivery and documented parental refusal of vitamin K prophylaxis (Zurynski et al., 2020).

The international data tells a consistent story across very different settings. In Thailand, before routine prophylaxis was introduced, late VKDB occurred in 72 per 100,000 births with a case fatality rate of 24 percent and intracranial haemorrhage in 82 percent of cases. After prophylaxis programs were established, the rate fell to between 4.2 and 7.8 per 100,000, a reduction of roughly 90 percent (Chuansumrit et al., cited in Mihatsch et al., 2021). In Japan, five successive nationwide surveys from 1981 to 2004 documented a nearly fourfold reduction in VKDB incidence as routine prophylaxis became established (Von Kries et al., 1999). In the United Kingdom, a two-year British Paediatric Surveillance Unit study identified 27 infants with VKDB: 20 had received no prophylaxis, 7 had received oral vitamin K, and zero had received the intramuscular injection, not a single IM-vaccinated infant developed the condition. The relative risk of VKDB with IM prophylaxis compared to no prophylaxis was 0.01 (McNinch and Tripp, cited in Von Kries et al., 1999). In Germany, IM prophylaxis was found to reduce the risk of late VKDB by 97 percent, compared to 80 percent with oral prophylaxis (Von Kries et al., 1999).

The bottom line on what the evidence shows:

• Without prophylaxis: up to 1,700 in every 100,000 newborns develop some form of VKDB.
• With a single IM injection: fewer than 1 in 100,000, a reduction of more than 99 percent.
• For late VKDB specifically (the form that causes brain bleeds): risk falls from up to 80 per 100,000 to fewer than 0.3 per 100,000.
• In a UK surveillance study, zero infants who received the IM injection developed VKDB across a two-year period.
• The same pattern whereby introduction reduces rates and withdrawal raises them has been documented across Thailand, Japan, Germany, the UK, Australia, and more.

What Is Actually in the Vitamin K Injection?

In Australia, the product used for newborn vitamin K prophylaxis is Konakion MM Paediatric, which contains 2 mg of phytomenadione in 0.2 mL. Phytomenadione is vitamin K1, the same form found naturally in leafy green vegetables, at a concentration appropriate for prophylactic use.

The "MM" in the name stands for mixed micelle, a modern formulation that uses glycocholic acid (a bile acid) and lecithin (a phospholipid) to keep the vitamin K suspended in solution. This formulation was specifically developed to improve bioavailability and eliminate the need for synthetic emulsifiers and preservatives that were used in older versions of the injection.

Importantly, the Konakion MM formulation used in Australian hospitals contains no benzyl alcohol (a preservative that was found to cause toxicity at high doses in premature infants in earlier formulations) and no heavy metals. Heavy metals are not ingredients in this product. This matters because a significant portion of online concern about the injection centres on its supposed chemical content. Much of that concern is based on outdated information about formulations that are no longer in use, or outright misinformation about ingredients that were never in the product.

What is actually in the Konakion MM Paediatric injection:

• Active ingredient: Phytomenadione (vitamin K1) — 2 mg in 0.2 mL
• Carriers: Glycocholic acid (a naturally occurring bile acid) and lecithin (a phospholipid also found in egg yolk and soy)
• Solvent: Water for injections
• No benzyl alcohol, no synthetic preservatives, no heavy metals as ingredients. Any trace elements present are manufacturing impurities governed by strict TGA pharmacopeial limits, the same standard applied to all injectable medicines in Australia.

Addressing the Concerns You May Have Read Online

If you have spent any time researching the vitamin K shot, you will have encountered a number of recurring concerns. Most are addressable with evidence. Some are understandable given how health misinformation spreads online.

Does the vitamin K shot contain dangerous levels of heavy metals or aluminium?

This claim circulates widely but does not hold up under scrutiny. To understand why, it helps to understand where trace metals come from in any injectable medicine, because the vitamin K shot is not unique in this respect.

Heavy metals are not ingredients in the Konakion MM formulation. They can appear in any pharmaceutical product as trace manufacturing impurities from three main sources:

• Glass vials and ampoules: Pharmaceutical-grade borosilicate glass contains aluminium oxide as part of its composition. Tiny amounts leach into the liquid over time during storage. This is a known, well-characterised property of glass packaging, not a contamination failure.
• Raw ingredient sources and water: The chemicals used to manufacture the product are extremely pure but not perfectly so. Elements including lead, arsenic, cadmium, and mercury can be present at parts-per-billion levels in starting materials derived from natural sources.
• Stainless steel manufacturing equipment: Processing equipment contributes trace amounts of chromium, nickel, and iron to some products during production.

All of these elements are tested under the ICH Q3D elemental impurity framework, the international regulatory standard adopted by the TGA. It sets a Permitted Daily Exposure value for each element, calculated from toxicology data and set far below any level associated with physiological harm. Every batch of Konakion MM Paediatric must demonstrate compliance with these limits before release.

On aluminium specifically, because it is the element most frequently named in online claims: the maximum content detected in the vitamin K injection is approximately 0.05 micrograms per dose. The daily allowable exposure for a 3 kg newborn is roughly 15 micrograms per kilogram of body weight. That single injection represents approximately 0.33 percent of the daily allowable limit (Science Feedback, 2022). 

When someone states that the vitamin K shot "contains heavy metals," they are technically correct in the same way it is technically correct to say tap water contains lead. What they are implying is that these elements are present as deliberate ingredients at doses of concern, and this is not supported by what the product actually contains or how pharmaceutical manufacturing works.

Was there a link between vitamin K injections and childhood leukaemia?

In 1992, a paper by Golding and colleagues published in the BMJ reported a statistical association between intramuscular vitamin K and childhood cancer. This study caused significant concern and, in some countries, contributed to a temporary shift toward oral prophylaxis. What is important to understand now is what the subsequent body of research found.

Multiple large-scale follow-up studies found no evidence of a causal link between intramuscular vitamin K and childhood leukaemia or any other cancer. These included the UK Childhood Cancer Study involving over 6,000 children with cancer compared to healthy controls, and a major study published in the New England Journal of Medicine by Klebanoff and colleagues in 1993 (Klebanoff et al., 1993; Roman et al., 2002). The current scientific and clinical consensus, held by organisations including the Australian NHMRC, RACP, WHO, and AAP, is that no such association exists. The 1992 Golding study is considered an example of a statistical association that did not survive replication.

Does vitamin K cause jaundice?

High-dose administration of early water-soluble vitamin K analogues (particularly menadione, also called vitamin K3) was associated with elevated bilirubin levels and a form of haemolytic anaemia, particularly in premature infants. Those formulations were withdrawn from use in 1961. The phytomenadione (K1) formulation used today at standard newborn doses is not associated with clinically significant jaundice in healthy term infants (SA Health, 2022).

Didn't babies survive for thousands of years without it? Maybe low vitamin K at birth is intentional.

This is one of the more thoughtful questions raised in this space, and it deserves a serious answer rather than a dismissal.

The first part of the argument is factually accurate: humans have been having babies for thousands of years, and the vitamin K shot has only been routine since the 1960s. Most babies were born and survived. But the evidence picture here is more complicated than that framing suggests.

Pre-modern infant mortality was substantially higher than it is today. Many of the conditions that killed infants in earlier centuries, including unexplained bleeding, seizures, and sudden neurological deterioration in otherwise healthy newborns, were poorly understood and not attributable to specific causes. What we now recognise as late VKDB would have been invisible in historical records. The absence of a documented name for a condition does not mean the condition was absent. Neonatal bleeding was, in fact, formally described as a distinct clinical pattern in 1894 precisely because physicians had been observing it in otherwise healthy newborns for as long as records existed.

The second part of the argument is genuinely interesting from a biological standpoint: is low vitamin K at birth intentional? Does it serve a purpose? Some researchers have noted that the relatively low clotting activity in a newborn's first hours may offer some physiological benefit, for example reducing the risk of clot formation during the compression and stress of the birth process itself. This is biologically plausible and worth acknowledging honestly.

What the research has not demonstrated is that this proposed benefit outweighs the documented harm when clotting is sufficiently compromised. The question is not whether low vitamin K at birth has any possible function. It is whether the subset of infants who develop VKDB, which causes intracranial haemorrhage in 30 to 50 percent of late cases, experience a protective benefit that justifies the risk. The evidence does not support that position.

It is also worth noting that modern birth practices differ significantly from those of earlier generations. Instrumental deliveries using forceps or vacuum increase physical stress on the baby's head and are associated with higher VKDB risk. Caesarean sections, induction of labour, and the use of certain medications during labour all introduce variables that were absent from most historical births. The risk profile of a baby born in 2025 in an Australian hospital is not identical to that of a baby born 300 years ago in a different environment, with a different birth pattern, different gut-seeding processes, and different early feeding practices.

Respecting the intelligence of the question does not mean the conclusion holds up under scrutiny. The honest position is: we do not know with certainty whether low neonatal vitamin K serves a purpose, but we know with substantial evidence what happens to a meaningful number of infants when that low level tips into a bleeding event.

Is the vitamin K shot offered primarily for the benefit of pharmaceutical companies?

This framing is worth engaging with honestly rather than dismissing. The premise suggests that VKDB is not a genuine condition, or that its severity has been exaggerated to generate profit from a routine medication.

The evidence does not support this. VKDB was first described in 1894, long before modern pharmaceutical infrastructure existed. The research that led to routine prophylaxis was conducted in academic and hospital settings across multiple countries over several decades. The condition it prevents has measurable, documented outcomes in unprotected populations, including the Australian APSU data showing 6 infant deaths across 24 years, 3 of which were directly linked to prophylaxis refusal. Konakion MM is not a patented blockbuster medication; it is a generic vitamin preparation. The proposition that its administration represents a profit motive does not align with the evidence or the economics of the product.

Summary of what the evidence shows on the common concerns:

• Heavy metals and aluminium: Not ingredients. Trace impurities from manufacturing are present at levels representing a fraction of a percent of daily allowable limits, the same as every other injectable medicine in Australia.
• Leukaemia link: One 1992 study reported an association. Multiple large-scale follow-up studies, including the UK Childhood Cancer Study, found no causal link. The association did not survive replication.
• Jaundice: Associated only with a high-dose formulation withdrawn in 1961. Not applicable to the current product at standard doses.
• Pharmaceutical profit motive: VKDB was documented in 1894, before modern pharmaceutical industry. The active ingredient is a generic vitamin. The evidence base was built in academic and hospital settings across multiple countries over decades.
• "Babies were fine before it existed": Most were. Pre-modern infant mortality was substantially higher, and VKDB deaths were not separately counted. Modern birth practices including instrumental delivery also change the risk profile.

What Are the Actual Options? Injection or Oral?

In Australia, two forms of prophylaxis are available: the intramuscular injection and an oral regimen. Both are discussed in the NHMRC guidelines, and both carry the official recommendation for universal use. However, they are not equivalent in effectiveness.

Method	Dosing	Late VKDB incidence (per 100,000)	Notes
IM injection	1 mg at birth (single dose)	<0.3	Preferred route; highest reliability; suitable for all term infants
Oral (full compliance)	2 mg at birth, day 3–5, week 4	1.5–1.8	Requires three separate doses; appropriate for healthy full-term infants only
Oral (intention-to-treat)	As above	2.5–2.6	Reflects real-world compliance rates
Single oral dose only	2 mg at birth	1.5–6.5	Not recommended; highly variable protection

The oral option is not recommended for preterm infants, unwell or unfed babies, infants whose mothers took enzyme-inducing medications during pregnancy, or any infant with suspected liver or bile duct problems, because oral vitamin K absorption depends on a functioning digestive system. For healthy full-term infants, oral prophylaxis does reduce VKDB risk, but consistently delivers less protection than the injection, particularly against the late form of VKDB where the stakes are highest.

What Does the Process Actually Look Like?

Because the first hours after birth can feel like a blur, it can help to know what to expect before you arrive.

The vitamin K injection is typically offered within the first hour after birth, often during the initial newborn check. The injection is given into the outer thigh (the anterolateral thigh muscle). It is a very small volume (0.2 mL) and takes only a few seconds. Most babies react briefly and then settle, particularly if they are skin-to-skin with a parent or feeding at the breast, both of which support comfort during the procedure.

If you have opted for the oral regimen, the first dose is given at birth in the same window. You will then need to return for a second dose at days 3 to 5, and a third dose at week four. It is important to let your midwife or paediatrician know if your baby vomits within an hour of receiving an oral dose, as this may require the dose to be repeated.

Either way, the conversation with your midwife or hospital staff is the right place to confirm the approach and ask any questions. Consent for the vitamin K injection is typically part of the routine newborn discussion before or shortly after birth.

Is Vitamin K Available for Homebirths?

Yes. Vitamin K prophylaxis is available for homebirths in Australia. Registered midwives attending homebirths carry Konakion MM Paediatric and are authorised to administer it. If you are planning a homebirth and want to ensure vitamin K is offered, confirm the plan with your midwife during your antenatal care. This is a straightforward conversation that most midwives initiate as a standard part of birth planning.

Which Countries Offer Routine Vitamin K Prophylaxis?

Universal newborn vitamin K prophylaxis is standard practice across Australia, the United Kingdom, the United States, Canada, Germany, France, the Netherlands, New Zealand, and most high-income countries. The WHO has included phytomenadione on its Essential Medicines List, and as of 2023, the mixed micelle formulation is used across more than 40 countries (WHO EML Expert Committee, 2025).

In some lower-income countries, availability is limited by cost and supply chain constraints rather than clinical disagreement with the evidence. In countries where access has been patchy or oral-only programs have been adopted, documented increases in VKDB rates have followed. This pattern across geographically and culturally diverse settings has been one of the strongest signals supporting the effectiveness of universal IM prophylaxis.

What Do the Current Australian Guidelines Recommend?

The NHMRC, in its Joint Statement on vitamin K (2010, with no evidence of need for change identified by the working committee), recommends that all newborn infants should receive vitamin K prophylaxis. The preferred route is a single 1 mg intramuscular injection of Konakion MM Paediatric at birth or shortly after. The oral regimen (three doses) is acknowledged as an alternative for healthy full-term infants but is explicitly noted to carry a higher risk of non-compliance and less reliable protection (NHMRC, 2010; RACP, 2019).

The RACP (Royal Australasian College of Physicians) and RANZCOG (Royal Australian and New Zealand College of Obstetricians and Gynaecologists) are aligned with this position. There is no current clinical body in Australia recommending withholding vitamin K prophylaxis from healthy newborns.

What Are the Actual Risks of the Injection?

The risks of the vitamin K injection are real, though small. They include:

• Pain and localised reaction at the injection site: Brief discomfort and possible redness or swelling at the injection site are the most common responses. These resolve quickly.
• Rare hypersensitivity reactions: Very rare allergic reactions have been reported with intravenous vitamin K administration (primarily in adults receiving larger doses). The incidence with standard newborn IM dosing is considered exceptionally rare.
• Elevated bilirubin in preterm infants: At standard doses in term infants, this is not a clinical concern. The guideline adjusts dosing for preterm infants (0.5 mg for those under 1,500 g) to account for this.

The risk of the injection is genuinely small. This does not mean it is zero, and parents have the right to understand that. What the evidence requires is that this small risk be held alongside the risk profile of the condition it prevents. By any clinical measure, the risk of leaving an exclusively breastfed infant without any prophylaxis is substantially higher than the risk of the injection itself.

Is Vitamin K Refusal Increasing, and Why?

Yes, and this is a documented trend in Australia and internationally. Queensland data shows vitamin K injection uptake falling from 98.3 percent in 2016 to 95.5 percent in 2025. Tasmania recorded a drop from 99 percent to 97 percent in the same period. While a 2 to 3 percentage point decline may sound small, it translates to thousands of additional unprotected infants each year across those states alone, and health professionals note the trend appears to be national (ABC News, 2026).

Internationally, the pattern is sharper. In the United States, parental refusal of the vitamin K injection nearly doubled between 2017 and 2024, rising from 2.9 percent to 5.2 percent (Medscape, 2026).

The primary driver identified by clinicians and public health researchers is social media misinformation. Claims circulating across platforms have included characterisations of the injection as containing dangerous chemicals, links to jaundice or leukaemia, and framing it as a pharmaceutical profit exercise rather than a genuine preventive intervention. Several of these claims relate to formulations no longer in use, or to dose levels that bear no relationship to standard newborn prophylaxis. The APSU 24-year Australian data, showing that three of six infant deaths from VKDB were directly linked to prophylaxis refusal, reflects why clinicians and public health authorities consider this trend a serious concern (Zurynski et al., 2020).

Key Takeaways: What the Evidence Shows

• Newborns are physiologically low in vitamin K at birth due to poor placental transfer, low levels in breast milk, and the absence of gut bacteria. This is not preventable through diet alone.
• Vitamin K deficiency bleeding (VKDB) is a real and documented condition. Without prophylaxis, late VKDB occurs in up to 80 per 100,000 breastfed infants and carries significant risk of intracranial haemorrhage and permanent neurological damage.
• Routine intramuscular vitamin K prophylaxis has reduced VKDB incidence from approximately 1,700 per 100,000 births to fewer than 1 per 100,000 in countries with universal programs.
• In Australia from 1993 to 2017, 6 infants died from VKDB. Three of those deaths were linked to home delivery and parental refusal of prophylaxis.
• The Konakion MM Paediatric injection used in Australia contains phytomenadione (vitamin K1) in a modern mixed micelle formulation. It does not contain benzyl alcohol or clinically significant levels of aluminium or heavy metals.
• The proposed link between IM vitamin K and childhood leukaemia has been extensively investigated and not confirmed. Multiple large studies, including the UK Childhood Cancer Study, found no causal association.
• The oral regimen is an available alternative but provides less reliable protection against late VKDB, requires three doses over four weeks, and is not appropriate for all infants.
• Vitamin K prophylaxis is available for homebirths in Australia through registered midwives.
• Uptake is declining in Australia, primarily driven by social media misinformation, a trend associated with documented infant harm internationally.

Making the Decision

The vitamin K shot is one of many decisions you will be asked to make in the birth space, and like all of them, it deserves your full attention rather than a reflexive yes or reflexive no. What you now have is the core evidence: what the condition is, what the intervention does, what is actually in the injection, what the research found about the commonly raised concerns, and what happens in populations where uptake declines.

If you have specific concerns about your circumstances (your own health, your birth setting, or any medications you have taken in pregnancy that may affect your baby's clotting), speak with your midwife, GP, or obstetrician before your birth date. They can walk through the detail that applies specifically to your situation. This is particularly important if you are planning a homebirth or are considering the oral regimen as an alternative, so you understand exactly what is involved and what level of follow-through the oral route requires.

Informed consent is the standard. Real informed consent means understanding both sides of the equation, not just one.

All content and media on the Mother Natal website are created and published online for informational purposes only. It is not intended to substitute professional medical advice and should not be relied on as health or personal advice.

Frequently Asked Questions

When exactly is the vitamin K injection given to my baby? The injection is typically offered within the first hour after birth, during the initial newborn assessment. It is given as a small injection into the outer thigh muscle. Your midwife or paediatrician will ask for your consent before administering it. In most settings this conversation happens antenatally as part of birth planning, so you are not making the decision in the room for the first time.

Can I decline the vitamin K injection and choose oral instead? Yes, the oral regimen is an alternative available in Australia for healthy full-term infants. It involves three doses: at birth, at days 3 to 5, and at four weeks. The oral route provides meaningful protection, but research consistently shows it is less effective than the single IM injection against late VKDB, the most serious form. It is also not suitable for preterm infants, unwell babies, or infants whose mothers took certain medications during pregnancy. Discuss this with your care provider well before your birth date if you are considering the oral option.

Is the vitamin K injection safe for babies born at home? Yes. Registered midwives attending planned homebirths in Australia carry Konakion MM Paediatric and are authorised to administer it. The clinical evidence and guidelines are the same regardless of birth setting. If you are planning a homebirth and want to confirm the approach, raise it directly with your midwife during antenatal care.

My baby received the vitamin K injection and now has jaundice. Is there a connection? This is a common concern but the current evidence does not support a causal link between the vitamin K injection and jaundice in healthy term infants at standard doses. Neonatal jaundice is extremely common, affecting roughly 60 percent of term newborns in the first week, and its timing can coincide with the vitamin K injection without being caused by it. The association between vitamin K and elevated bilirubin was documented with older, high-dose water-soluble formulations that were withdrawn from use in 1961. If you are concerned about your baby's jaundice levels, speak with your midwife or paediatrician.

Does the vitamin K injection contain heavy metals or aluminium? Heavy metals are not ingredients in the Konakion MM Paediatric formulation used in Australia. Like all TGA-registered injectable medicines, it is tested against strict pharmacopeial purity standards for manufacturing trace impurities, but this applies equally to every medicine available in Australia, including paracetamol. On aluminium specifically: the maximum content in the vitamin K injection is approximately 0.05 micrograms, representing roughly 0.33 percent of the daily allowable aluminium exposure for a newborn. The concerns about heavy metals and toxic ingredients that circulate online do not reflect what is actually in this product.

I have read that vitamin K injections are linked to childhood leukaemia. Is this true? This concern originates from a single 1992 study by Golding and colleagues that reported a statistical association. Multiple large follow-up studies, including the UK Childhood Cancer Study (the largest to date, involving thousands of children with cancer compared to healthy controls) and a study published in the New England Journal of Medicine, found no evidence of a causal link. The current consensus across the NHMRC, RACP, AAP, and WHO is that no association between IM vitamin K at standard newborn doses and childhood cancer has been established.

What happens if VKDB is not caught quickly? Late VKDB, the form that typically presents between two and twelve weeks of age, often has few warning signs before a serious bleed occurs. The most severe presentation is intracranial haemorrhage. Research shows that 30 to 50 percent of late VKDB cases involve brain bleeding, and of infants who survive, approximately 40 to 55 percent have permanent neurological damage. The difficulty is that VKDB can be clinically silent until a critical bleed occurs, which is exactly why prevention is prioritised over watchful waiting.

Does the vitamin K injection affect breastfeeding? No. The injection does not interfere with breastfeeding. The brief discomfort from the injection typically settles within a few minutes, and breastfeeding immediately before or after the procedure can support comfort and settling. Some parents find that giving the injection during a feed helps their baby manage the short-term discomfort.

Are there any babies who should not receive the vitamin K injection? The IM injection is appropriate for the vast majority of term newborns. The dose is adjusted to 0.5 mg for preterm infants under 1,500 grams. Infants with certain rare clotting disorders require specialist advice before administration. Speak with your care provider if there is any family history of clotting abnormalities or if your baby appears unwell at birth.

Is low vitamin K at birth natural and intentional? Should we be interfering with that? It is possible that low clotting activity in the first hours after birth has some physiological role, and some researchers have proposed it may reduce clot risk during the birth process. What has not been demonstrated is that this benefit, if it exists, outweighs the documented harm to infants who develop VKDB. The biology of a newborn born in 2025, often following instrumental delivery or other modern interventions, is not identical to the biology of a newborn in a pre-medical context. Most infants are born fine without prophylaxis. The concern is the subset who are not, and in that subset the outcomes can be severe and irreversible.

Why is the rate of parents refusing vitamin K increasing? Clinicians and researchers have consistently pointed to social media misinformation as the primary driver. Many of the claims circulating online reference outdated formulations, misrepresent ingredient data, or draw on studies that have not been replicated. The concern is not simply ideological. Declining uptake in both Australia and internationally has been followed by documented increases in VKDB cases in affected regions. This is why Australian health authorities have increasingly prioritised public communication around the evidence base for vitamin K prophylaxis.

References

Ardell, S., Offringa, M., Ovelman, C. and Soll, R. (2010). Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/29401369/

Australian Broadcasting Corporation (ABC News) (2026). 'More Australian parents refusing vitamin K for newborns amidst online misinformation', 26 July. Available at: https://www.abc.net.au/news/2026-07-26/parents-refusing-lifesaving-vitamin-k-injection-for-newborns/106938860.

Golding, J., Greenwood, R., Birmingham, K. and Mott, M. (1992). Childhood cancer, intramuscular vitamin K, and pethidine given during labour. British Medical Journal, 305(6849), pp. 341–346. https://pubmed.ncbi.nlm.nih.gov/1392886/

Klebanoff, M.A., Read, J.S., Mills, J.L. and Shiono, P.H. (1993). The risk of childhood cancer after neonatal exposure to vitamin K. New England Journal of Medicine, 329(13), pp. 905–908. https://pubmed.ncbi.nlm.nih.gov/8361503/

Medscape (2026). 'More Parents Declining Vitamin K Shot for Newborns'. Available at: https://www.medscape.com/viewarticle/more-parents-declining-vitamin-k-shot-newborns-2026a10007ny

Mihatsch, W.A., Braegger, C., Bronsky, J., Campoy, C., Domellöf, M., Fewtrell, M., Mis, N.F., Hojsak, I., Hulst, J., Indrio, F., Lapillonne, A., Molgaard, C., Vora, R. and van Goudoever, J. (2021). Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition, 63(1), pp. 123–129. https://pubmed.ncbi.nlm.nih.gov/27050049/

National Health and Medical Research Council (NHMRC) (2010). Joint Statement: Vitamin K for Newborn Babies. Australian Government: Canberra. Available at: https://www.nhmrc.gov.au/health-advice/childrens-health-and-development/vitamin-k-newborns. 

Royal Australasian College of Physicians (RACP) (2019). Vitamin K Administration to Newborn Infants: Policy Statement. Available at: https://www.racp.edu.au/docs/default-source/advocacy-library/vitamin-k-administration-to-newborn-infants---policy-statement.pdf . 

Roman, E., Fear, N.T., Ansell, P., Bull, D., Draper, G., McKinney, P., Michaelis, J., Passmore, S.J. and Watson, A. (2002). Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies. British Journal of Cancer, 86(1), pp. 63–69. https://pubmed.ncbi.nlm.nih.gov/11857013/

SA Health (2022). South Australian Neonatal Medication Guidelines: Vitamin K. Government of South Australia. https://www.sahealth.sa.gov.au/

ICH Q3D Guideline for Elemental Impurities. Adopted by the Therapeutic Goods Administration (TGA). https://www.tga.gov.au/resources/resources/international-scientific-guidelines-adopted-australia/ich-guideline-q3d-r2-elemental-impurities

Science Feedback (2022). 'Addressing false claims that vitamin K shots have toxic levels of aluminium'. Available at: https://science.feedback.org/review/addressing-false-claims-vitamin-k-shots-toxic-aluminum-hepatitis-b-vaccines-toxic-ingredients/ . 

Majid A, Blackwell M, Broadbent RS, Barker DP, Al-Sallami HS, Edmonds L, Kerruish N, Wheeler BJ. Newborn Vitamin K Prophylaxis: A Historical Perspective to Understand Modern Barriers to Uptake. Hosp Pediatr. 2019 Jan;9(1):55-60. https://pubmed.ncbi.nlm.nih.gov/30593456/

Texas Children's Hospital (2023). 'Dispelling myths: vitamin K injections for newborns'. Available at: https://www.texaschildrens.org/content/wellness/dispelling-myths-vitamin-k-injections-for-newborns

McNinch, A. and Tripp, J.H. (1991). Haemorrhagic disease of the newborn in the British Isles: two year prospective study. British Medical Journal, 303(6802), pp. 1105–1109. https://pmc.ncbi.nlm.nih.gov/articles/PMC1671305/

Von Kries, R., Hachmeister, A. and Göbel, U. (1999). Late form of vitamin K deficiency bleeding in Germany. European Journal of Pediatrics, 158(Suppl 3), pp. S172–S177. https://pubmed.ncbi.nlm.nih.gov/7623433/

World Health Organization (WHO) Expert Committee on the Selection and Use of Essential Medicines (2025). Application for the inclusion of phytomenadione as mixed micelle (MM) solution on the WHO Model List of Essential Medicines. Available at: https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/new-formulations-strengths-of-existing-medicines/f.2_phytomenadione.pdf. 

Zurynski Y, Grover CJ, Jalaludin B, Elliott EJ. (2020). Vitamin K deficiency bleeding in Australian infants 1993–2017: an Australian Paediatric Surveillance Unit study. https://pubmed.ncbi.nlm.nih.gov/31519552/